96 related articles for article (PubMed ID: 15125945)
21. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
[TBL] [Abstract][Full Text] [Related]
22. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity.
Ahn HS; Bercovici A; Boykow G; Bronnenkant A; Chackalamannil S; Chow J; Cleven R; Cook J; Czarniecki M; Domalski C; Fawzi A; Green M; Gündes A; Ho G; Laudicina M; Lindo N; Ma K; Manna M; McKittrick B; Mirzai B; Nechuta T; Neustadt B; Puchalski C; Pula K; Zhang H
J Med Chem; 1997 Jul; 40(14):2196-210. PubMed ID: 9216839
[TBL] [Abstract][Full Text] [Related]
23. A new chemical tool for exploring the physiological function of the PDE2 isozyme.
Chambers RJ; Abrams K; Garceau NY; Kamath AV; Manley CM; Lilley SC; Otte DA; Scott DO; Sheils AL; Tess DA; Vellekoop AS; Zhang Y; Lam KT
Bioorg Med Chem Lett; 2006 Jan; 16(2):307-10. PubMed ID: 16275071
[TBL] [Abstract][Full Text] [Related]
24. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterases: the journey towards therapeutics.
Torphy TJ; Page C
Trends Pharmacol Sci; 2000 May; 21(5):157-9. PubMed ID: 10885973
[No Abstract] [Full Text] [Related]
26. Constitutively activated phosphatidylinositol 3-kinase primes platelets from patients with chronic myelogenous leukemia for thrombopoietin-induced aggregation.
Kubota Y; Tanaka T; Ohnishi H; Kitanaka A; Okutani Y; Taminato T; Ishida T; Kamano H
Leukemia; 2004 Jun; 18(6):1127-37. PubMed ID: 15085152
[TBL] [Abstract][Full Text] [Related]
27. Cyclic nucleotides and phosphodiesterases in platelets.
Haslam RJ; Dickinson NT; Jang EK
Thromb Haemost; 1999 Aug; 82(2):412-23. PubMed ID: 10605732
[No Abstract] [Full Text] [Related]
28. Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei.
Zoraghi R; Kunz S; Gong K; Seebeck T
J Biol Chem; 2001 Apr; 276(15):11559-66. PubMed ID: 11134002
[TBL] [Abstract][Full Text] [Related]
29. Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4.
Favot L; Keravis T; Lugnier C
Thromb Haemost; 2004 Sep; 92(3):634-45. PubMed ID: 15351862
[TBL] [Abstract][Full Text] [Related]
30. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
[TBL] [Abstract][Full Text] [Related]
32. Relative potencies of dipyridamole and related agents as inhibitors of cyclic nucleotide phosphodiesterases: possible explanation of mechansim of inhibition of platelet function.
McElroy FA; Philip RB
Life Sci; 1975 Nov; 17(9):1479-93. PubMed ID: 173959
[No Abstract] [Full Text] [Related]
33. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B.
Zhang W; Ke H; Tretiakova AP; Jameson B; Colman RW
Protein Sci; 2001 Aug; 10(8):1481-9. PubMed ID: 11468344
[TBL] [Abstract][Full Text] [Related]
34. Long-term regulation of cyclic nucleotide phosphodiesterase type 3B and 4 in 3T3-L1 adipocytes.
Oknianska A; Zmuda-Trzebiatowska E; Manganiello V; Degerman E
Biochem Biophys Res Commun; 2007 Feb; 353(4):1080-5. PubMed ID: 17198676
[TBL] [Abstract][Full Text] [Related]
35. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
[TBL] [Abstract][Full Text] [Related]
36. Regulation of adiponectin and leptin secretion and expression by insulin through a PI3K-PDE3B dependent mechanism in rat primary adipocytes.
Cong L; Chen K; Li J; Gao P; Li Q; Mi S; Wu X; Zhao AZ
Biochem J; 2007 May; 403(3):519-25. PubMed ID: 17286556
[TBL] [Abstract][Full Text] [Related]
37. Characterization of renal ecto-phosphodiesterase.
Jackson EK; Ren J; Zacharia LC; Mi Z
J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
[TBL] [Abstract][Full Text] [Related]
38. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
40. IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells.
Ahmad F; Gao G; Wang LM; Landstrom TR; Degerman E; Pierce JH; Manganiello VC
J Immunol; 1999 Apr; 162(8):4864-75. PubMed ID: 10202031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
